The Biophysicist is a new journal published by the Biophysical Society
At this moment, when the world is looking to science to provide solutions to the novel coronavirus pandemic, the speed with which the public authorities invest in research and innovation will be decisive for facing this crisis. The governments of different countries must cooperate strategically in a coordinated manner to provide the best way to deal with the virus. The State must promote and encourage scientific development, research, scientific and technological training, and innovation.
Only with sufficient resources and support for this new scientific challenge will we be able to provide an answer based on knowledge; the enemy is still unknown. Health, science and technology are interconnected, particularly during this health crisis that all countries in the world are going through with the emergence of novel coronavirus diseases (COVID-19).
It is urgent that world scientists are mobilized to cope with actions to support therapeutic research, vaccines and diagnostics, innovation for the development of equipment, and to strengthen the training of researchers to advance basic research that allows better conditions for discovery and strategies that can overcome or control the virus. In this context, basic scientific knowledge has a relevant role.
For this reason, the IUPAB is in solidarity with biophysicists and all scientists throughout the world so that together we can provide the answers that everyone expects from science and scientists to defeat this previously unknown enemy and minimize human suffering.
“If you do not know the enemy you will lose all battles” (Sun Tzu.General Chinese. Author of the book The Art of War).
We need more cooperative science between countries and international educational initiatives to contribute to the training of the new generation of scientists. The world needs them and is counting on them for the challenges of humanity.
I am sure that together we will overcome this challenge through science.
Marcelo Marcos Morales
We are all dealing with difficult times due to the coronavirus (COVID-19) pandemic. The situation has worsened significantly in Europe and USA, as well as elsewhere. Some of you may be in the rush to find new solutions to the pandemic and we wish all the success in your efforts. Although our event is still many months away, we cannot fight against reality and try to urge people to register or to buy international tickets at this time. Although the program was almost complete and very exciting, we took the hard decision to postpone IUPAB 2020 for ~1 year. We thank you for your patience and continued persistence, while we announce that IUPAB 2020 will be held in Foz do Iguaçu from 4 to 8th of October 2021.
We understand that this might come as a big disappointment to our chairs, speakers, exhibitors and participants looking forward to some wonderful days in Foz do Iguaçu. However, we do hope to be able to confirm your participation for the next year. We will be sending notifications to each registered participant soon with this information and more details concerning key dates, abstract and reservations.
Through these tough times, we do hope you can continue your teaching and research activities in different ways, to continue with the advances in Biophysics and Biochemistry, and all duties with your family. We also wish all the luck for all those working in fields relevant to addressing the pandemic.
We look forward to welcoming you to Foz do Iguaçu in happier times in 2021!
Rosangela Itri & Mauricio S. Baptista
Chairs of IUPAB 2020/2021
We reproduce due to his interest of this document from the Biophysical Society
Responding to the Coronavirus Threat through Investments in Fundamental Biomedical Research.
From the Public Affairs Committee of the Biophysical Society
The Coronavirus COVID-19 outbreak is putting enormous strains on our hospitals, health care providers and public health system. The immediate response to the pandemic is focused, necessarily, on tracking the progression of infection, limiting its spread through social distancing and other behavioral modifications, and treating the sickest infected individuals who are unable to recover on their own in self-quarantine. However, effectively containing and limiting the spread of COVID-19 also depend heavily on fundamental biomedical research being conducted right now, in large part because we know so little about this virus, the way in which it infects individuals, how the human immune system responds to it, and how it spreads from person to person. The future response to the pandemic needed to stop COVID-19 from returning seasonally and to eradicate it from the human population, as well as to responding to other, as yet unknown, emerging infectious diseases, depends almost entirely on the results of fundamental biomedical research yet to be conducted. These current and future research programs are not funded through Medicare, Medicaid or any health insurance provider. Rather, they depend on appropriations to federal agencies, such as the National Institutes of Health (NIH), the National Science Foundation (NSF) and the Department of Energy (DOE). COVID-19, as well as the next coronavirus or other infectious disease that could spark a global pandemic that kills millions and destroys economies worldwide, require substantial immediate and sustained increases in appropriations to NIH, NSF, DOE and other federal agencies that fund fundamental biomedical research.
The U.S. Congress just passed a $2 trillion stimulus package with major new investments in the economy and healthcare. To a much lesser extent, funding for fundamental biomedical research was also provided in this bill. Indeed, approximately $950 million was dedicated to supporting research efforts at the NIH. While this seems like a large amount of funding, it represents less than 0.05% of the stimulus package and only a 2.2% increase in the overall FY20 operating budget of the NIH; substantially less even than recent annual NIH budget increases. A significantly larger immediate and sustained increase in fundamental research funding will be needed to combat COVID-19 and to protect us from the inevitable next pandemic.
The 48-page NIH-Wide Strategic Plan 2016-2020 summary provides an excellent overview of budgetary needs required to address this crisis, and should be widely read. The Strategic Plan on vaccine adjuvants for the National Institute of Allergy and Infectious Disease (NIAID) is particularly important. Yet many critical research components for the coronavirus response are led by the roughly 35,000 NIH-funded Principal Investigators, working primarily at research universities and institutes across the nation, whose research is supported by other NIH Institutes and Centers. Supplemental funding to existing NIH grants through mechanisms recently instituted by some NIH institutes, such as NIDA and NIGMS, is one way in which to address these problems quickly and effectively. We recommend that similar steps be taken by the other NIH institutes and US research funding agencies. However, more needs to be done.
In terms of necessary fundamental and applied research, the budgetary response to the outbreak will require focused proposals identifying immediate increased investments, as well as longer term outlays to support a sustained response to this and future pandemics. Identified below are several critical areas of both fundamental and translational research, informed by the collective experience of Biophysical Society members, which require Congressional support for immediate and sustained increased funding in order to address the challenges posed by the current coronavirus pandemic, as well as to position our nation to respond quickly and effectively to the inevitable next pandemic outbreak.
Immediate fundamental biomedical research funding needs
Outlined below are areas of research and development that require substantial immediate increases in funding for fundamental biomedical research to effectively respond to COVID-19.
Sensitive and accurate tests exist for viral sequences and proteins that unambiguously indicate infection. However, increasing the speed of the tests and ensuring a robust supply line are key to their utilization, as demonstrated by the challenges faced in the February roll out of COVID-19 testing in the US.
- Initiatives to increase the speed of current polymerase chain reaction (PCR)-based testing methods through NIH, NSF and DOE should be established and explicitly funded.
- Programs to support the rapid development of novel tests that leverage non-PCR technologies that could have higher throughput and/or accuracy than current tests, such as serological tests currently under development.
- A new supply chain analysis unit should be established in the Centers for Disease Control and Prevention (CDC) in order to ensure that the biotechnology and pharmaceutical industries produce reagents for millions of testing kits.
Vaccines represent the best long-term response to infectious diseases, including COVID-19, as well as other coronaviruses and emerging pathogens. Vaccines protect healthy individuals from getting sick, stop the spread of disease and, in certain cases such as smallpox, can completely eradicate a particular virus from the world.
- The most effective vaccines currently in use are based on either purified but inactivated virus particles or purified subunits of the virus, for example the influenza hemagglutinin protein. Producing these proteins in the very high amounts needed to manufacture millions of doses requires understanding the mechanisms of production that the virus uses to make copies of its proteins such that it can generate new viruses and spread infection. Congress should appropriate funds adequate to expand substantially the existing NIAID-supported activities in this area.
- Development of vaccines requires testing with the actual infectious agents. This requires enhanced containment facilities for labs and animal facilities. Congress should appropriate funds to ensure institutions are in a position to carry out such testing and development, and can put in place the required containment facilities. NIAID should be provided with a dedicated fund to finance trials of new vaccine candidates.
Sustained fundamental biomedical research funding needs
Outlined below are areas of research and development that require substantial future sustained increases in funding for fundamental biomedical research to effectively respond to COVID-19 and other emerging infectious diseases. These needs can be broadly categorized into: (1) building the infrastructure required to apply the most advanced experimental techniques to understanding coronaviruses and other infectious diseases; and (2) biological studies to understand how viruses and other pathogens infect and replicate in humans and how the human immune system responds, or sometimes fails to respond, to these infectious agents.
Building Infrastructure for Fundamental Biomedical Research
In order to understand the possible targets for antibodies and anti-viral drugs, as well as to understand the steps involved in viral attachment to host cells, knowledge of the precise structures of all of the components of the virus are needed. This information is critical for the development of new vaccines and therapeutics to protect and treat individuals. The determination of the high-resolution three-dimensional structures of the viral particles, proteins, nucleic acids and membrane requires sophisticated instrumentation and facilities, including those for cryo-electron microscopy (cryo-EM), nuclear magnetic resonance (NMR), and X-ray diffraction. The purchase costs of these instruments are in the millions of dollars per instrument, and the annual budgets needed to keep each of these instruments working are often in the in the hundreds of thousands of dollars.
- Congress should substantially increase funding of existing facilities NMR, cryo-EM and X-ray diffraction facilities across the nation.
- In addition, the NIH and DOE budgets should be supplemented for dedicated increases in the X-ray diffraction beamlines at synchrotron facilities, such as at Argonne and Brookhaven National Laboratories.
- To provide the trained personnel needed to use these instruments, budgets for NIH Training Grants to support the next-generation of structural biologists in these areas should be increased.
Massive computational resources should also be harnessed in the fight against coronavirus and emerging infectious diseases. Computational biology is a key component of any research effort aimed at understanding and eventually mitigating disease. Funding initiatives to increase access to computational facilities at NIH, NSF and DOE, and to support computational research should be established and explicitly funded, including:
- Computational structural biology, which provides structural models of viral proteins and capsids that can be used in solving experimental structures and virtual screening of potential drugs. These methods can also characterize the dynamic properties of viral proteins and how these may be affected by the mutations which are sure to occur.
- Large, multi-scale simulations help to understand cellular processes and responses to changing conditions such as viral entry, reproduction and budding.
- Epidemiological simulations can track and predict viral spread, integrating real-time human travel data, epidemiological data and viral sequencing data to forecast the impact of potential public-health interventions and better project potential outbreak trajectories in the U.S. and across its borders.
Understanding Infection and Immunity
Biochemistry of Viral Replication:
Current effective targets of anti-viral drugs include the enzymes used by the virus to replicate their RNA and the proteases used by the virus to generate the nucleocapsid and other viral structural proteins – both of which are needed for the generation of new virus particles in the human body. NIH budgets for research on these enzymes and methods by which to inhibit their functions should be supplemented to support substantial expansion of research programs targeting this area.
The Immune Response:
The various types of white blood cells of the human immune system have evolved extremely sophisticated and effective mechanisms for detecting and counterattacking invaders, be they viruses, bacteria, fungi, parasites or toxins. However, many people infected with COVID-19 and other pathogens are unable to mount a sufficient immune response to fight off the virus. The extraordinary variation needed in the nature of the antibodies produced, and the generation of killer white cells that can recognize infected cells, leaves a great deal to be learned. Research in this area represents a key element of developing drugs and vaccines against COVID-19. The immune system protects us from all manner of pathogens, not just coronaviruses. We need to accelerate our understanding of all aspects of the immune system, both because of the importance in the design of vaccines, and in the body’s response to infection in the absence of prior vaccination. Congress should greatly increase funding for research focused on the immune system.
Call to Action
Today, we are witnessing how a single infectious disease can spread like wildfire through the world’s population, with utter disregard for its victims’ stations in life or countries of residence. This global pandemic is not only killing thousands but also changing the very norms of human interaction and shuttering economies around the world. Even when this coronavirus infection is tamed, its societal and economic impacts will be devastating and long-lasting. As certain as we can say that this generation has never experienced anything remotely like this, it is, unfortunately, entirely possible that we could relive this nightmare over and over again. As ill-prepared as we were for this pandemic, we remain equally undefended against the inevitable next emerging infectious disease that will rip through the human population. This situation is not inevitable. We can fight off this coronavirus, perhaps even vanquish it from humankind forever, and generate the knowledge and tools required to stop the next pandemic before it gains hold. This will take an investment in science, the likes of which we have not seen since the Sputnik era, if ever. Fundamental biomedical research is the only way to generate the knowledge of how pathogens with pandemic potential infect humans, how the human immune system responds to these infections, and how to leverage this understanding to develop new vaccines and drugs. It is not only our best weapon in eventually ending this pandemic, but also in preventing future pandemics from killing millions more and ravaging our economies and societies. We call upon our policymakers to implement transformative legislation for massive biomedical research funding now.
The first edition of the Avanti Polar Lipids-IUPAB Medal and Prize has been awarded to Prof. Anthony Watts for his pioneering contributions to biophysical research on membranes especially with the use of novel NMR techniques.
Tony Watts graduated from Leeds University, UK with a BSc and PhD in biophysics. After 5 years working at the Max Planck Institute for Biophysics, Göttingen, Germany studying lipid-protein interactions using functional studies combined with EPR and nitroxide spin labels, he was appointed to a tenure track position at Oxford University in 1980. Here he progressed to a full Professorship in 1996 and also secured, in 1983, and held the C. W. Maplethorpe endowed Fellowship at St Hugh’s College, Oxford, eventually becoming Vice-Principal.
In Oxford, Tony was a pioneer in the development of solid state NMR for biological systems, predominantly membranes. This work involved not only customization of NMR instrumentation for (lossy) biological systems, high fields (the first commercial wide bore 800MHz) as well as novel isotopic substitution chemistry to include NMR visible nuclei, especially deuterium and 13C into, especially, lipids, drugs and ligands. Some of these nitroxide and NMR labelled compounds are available today from Avanti. Tony holds patents covering new synthetic routes, as well as for lipid use in the food and leather industries, as evidence of translational applications.
More recently, Tony’s research has focussed on the development and characterization of polymer stabilized lipid nanoparticle technology to deliver drugs in a clinical context, and for (detergent-free) structural biology. Mass spec of lipids from an in vivo system (C. elegans) without compromising viability using polymer extraction, also shows promise for characterizing disease. The polymer technology has also enhanced crystallographic studies of novel photoreceptors, resulting in very high resolution receptor structures.
In all his research, functional characterization of a system has been a pre-requisite, despite the many challenges and difficulties in achieving this aim. Over 120 post-docs, almost 70 graduates and 10s of sabbatical workers, several from Brazil, have been trained and spent time in his lab. He was elected as a Fellows of the Royal Society of Chemistry, Royal Society of Biology, Institute of Physics (London) and the Biophysical Society, being one of the first non-US Fellows of the Society. Editorial work has included Biophysical Chemistry (9 years, managing editor), the European Biophysical Journal (15 years, managing editor), Biophysical Journal (6 years, associate editor) and he co-edits the Nature-Springer Encyclopaedia of Biophysics. He was chair (2000-2007; 2009-2017) of the British Biophysical Society (BBS) and President (2017-2019) of the European Biophysical Societies Association (EBSA), and is now an Honorary member of BBS and EBSA.
Prof. Watts is at University of Oxford, Department of Biochemistry.
The first Edition of the IUPAB Young Investigator Medal and Prize has been awarded to Dr Yoav Shechtman for his continuous attempt to develop new imaging tools for higher and higher resolution and applications in Biophysics.
Assistant Professor Yoav Shechtman leads the Nano-Bio-Optics lab at the Technion, Israel Institute of Technology. Yoav Finished all degrees at the Technion: BSc in Physics and Electrical Engineering (2007), Phd (2013), and then completed a postdoc at Stanford University (2016), developing super-resolution microscopy methods with W.E. Moerner.
His research interests lie mainly in developing and applying optical and signal processing methods for nanoscale imaging challenges. Specifically, Yoav focuses on aspects of single/multiple particle localization and tracking under challenging conditions, e.g. three-dimensional, multicolor, and high throughput imaging, using advanced signal processing and machine learning techniques. The techniques developed in the lab are applied to challenges ranging from basic science, i.e. observing chromatin dynamics in 3D, to biomedical applications, i.e. developing ultra-sensitive assays for bacterial growth.
Among Yoav’s recent awards and recognitions: 2016 Technion Career Advancement Chair, 2017 Zuckerman Faculty Scholar, 2018 Early Career Award of the International Association for Medical and Biological Engineering (IAMBE), 2018 European Research Council starting grant, 2019 Uzi and Michal Halevy Award for Innovative Applied Engineering.
Lab wesbite: http://nanobiooptics.net.technion.ac.il/